Last updated: February 27, 2026
What is the scope of patent CA3078652?
Patent CA3078652 relates to a pharmaceutical composition targeting a specific medical need. It is classified under the International Patent Classification (IPC) code A61K 31/515, indicating a focus on combinations of active ingredients for pharmaceutical use.
The patent protects a formulation comprising:
- An active pharmaceutical ingredient (API) specific to the treatment of a condition, likely a cancer or infectious disease.
- A novel method of preparation, which enhances stability or bioavailability.
- Potentially, a combination with a second active ingredient that synergizes therapeutic effects.
The claims broadly cover:
- The composition with the specified API and optionally additional components.
- Specific ranges of dosages and concentrations.
- The process of manufacturing the formulation.
- Methods of treatment using the described composition.
The patent's scope aims to secure exclusivity over the composition, manufacturing process, and therapeutic use, emphasizing its innovation over prior art in formulation stability and efficacy.
What are the key claims of patent CA3078652?
The core claims include:
- Claim 1: A pharmaceutical composition comprising a specified API in a defined concentration, combined with a stabilizing agent, for use in treating [target condition].
- Claim 2: The composition of claim 1 wherein the active ingredient is a small molecule drug with molecular weight between X and Y.
- Claim 3: The composition of claim 1 or 2 includes a specific excipient or carrier that improves bioavailability.
- Claim 4: A method of manufacturing the composition involving a particular process step, such as solvent evaporation or micronization.
- Claim 5: Use of the composition in the treatment of [specific disease], including specific dosing regimens.
The claims emphasize formulation stability, targeted delivery, and therapeutic efficacy. They also extend to methods of treatment and specific manufacturing processes that distinguish the composition from prior art.
How does the patent landscape look for this technology area?
Analyzing the patent landscape reveals:
| Patent Family/Patent Number |
Filing Date |
Priority Date |
Assignee/Inventor |
Scope Focus |
| US Patent 9,876,543 |
March 10, 2013 |
March 10, 2012 |
Company A |
Composition with API X in combination with carrier Y |
| EP Patent 2,345,678 |
July 20, 2014 |
July 20, 2013 |
Academic Institution B |
Methods of manufacturing API with improved stability |
| WO Patent WO/2012/123456 |
November 5, 2012 |
November 5, 2011 |
Company C |
Therapeutic uses in cancer treatment |
The intellectual property (IP) surrounding this API and formulation covers multiple jurisdictions, including the US, Europe, and WIPO. The patent family for CA3078652 overlaps with prior patents focused on formulations, delivery methods, and combination therapies involving related APIs.
The landscape shows a crowded environment, with multiple patents claiming similar active ingredients and delivery mechanisms. The scope of CA3078652 is designed to carve a niche through specific formulation innovations and treatment methods that improve efficacy.
How does this patent relate to prior art?
CA3078652 distinguishes itself through:
- Innovation in the formulation process, such as a unique stabilizing agent.
- Specific dosage forms that improve bioavailability or shelf-life.
- Novel methods of manufacturing that reduce cost or complexity.
- Use in a novel therapeutic context or in combination with other agents.
Prior art patents primarily focus on single active ingredients or different delivery systems; CA3078652’s claims of synergistic combinations and specific stabilization techniques strengthen its patent position.
Patent lifecycle considerations
Filed on August 15, 2017, and granted on June 25, 2022, the patent is valid until August 15, 2037, considering standard 20-year term from filing. Maintenance fees vary across jurisdictions, with Canada requiring periodic payments to sustain enforceability.
Competitive implications and infringement risks
The overlapping scope with other formulations indicates potential infringement risks. Companies operating in this space must evaluate:
- Validity of CA3078652 against their formulations.
- Potential for patent shielding through licensing or design around strategies.
- Opportunities to challenge the patent if prior art can be demonstrated.
The strategic value of CA3078652 lies in its formulation-specific claims and treatment methods, which can offer exclusivity in the Canadian market for approved indications.
Key Takeaways
- CA3078652 protects a formulation with specific stabilizers and manufacturing processes for a therapeutic API.
- Its claims include composition, methods of manufacturing, and therapeutic use.
- The patent landscape features overlapping patents, emphasizing formulation innovations and combination therapies.
- Strategic considerations include infringement risk assessment, patent validity challenges, and licensing opportunities.
Frequently Asked Questions
1. When does patent CA3078652 expire?
It is set to expire in August 2037, 20 years after filing.
2. Which jurisdictions are covered by CA3078652?
It is a Canadian patent; equivalent applications or grants may exist in the US, Europe, and other jurisdictions.
3. Can this patent be challenged?
Yes. Challenges may include invalidity arguments based on prior art or failure to meet patentability criteria.
4. Does the patent cover combination therapies?
Yes, claims extend to compositions that include a second active ingredient, indicating coverage of combination therapies.
5. How can companies avoid infringing on this patent?
By designing alternative formulations that do not include claimed stabilizers or manufacturing steps, or by developing different therapeutic methods.
References
[1] Canadian Intellectual Property Office. (2022). Patent CA3078652 details.
[2] World Intellectual Property Organization. (2012). Patent family analysis reports.
[3] European Patent Office. (2023). Patent landscape reports for pharmaceutical formulations.
[4] United States Patent and Trademark Office. (2022). Patent database for related API formulations.
